Type 2 diabetes accounts for nearly 90% of all diabetic cases, with approximately 200 million people worldwide that suffer from the disease. This research describes the successful synthesis of three novel compounds that exhibit anti-diabetic capabilities. These compounds stimulate the release of glucagon-like peptide-1 (GLP-1), an incretin that stimulates the secretion of insulin and inhibits the release of glucagon leading to decreased levels of blood glucose. The synthesis occurred in a three-step route for Compound 1 and Compound 2. The first step, a reductive amination, was done in 75% and 88% yield for Compound 2 and Compound 1, respectively. The second step, an acylation, was done in 70% yield. The third step, a SN2, was done in about 50% yield for both. The synthesis of Compound 3 was carried out via a four-step route. The first step, a difluoromethylation, was carried out in 55% yield. The second step, a reductive amination, was done in 96% yield. The third step, an acylation, was done in 70% yield. The fourth step, a SN2, had a yield of about 50%. All three of the final products were characterized using 1H NMR, 13C NMR, and mass spectroscopy.

Synthesis of novel blood sugar lowering compounds

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.